PMID- 37129721
OWN - NLM
STAT- MEDLINE
DCOM- 20230928
LR  - 20231220
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Linking)
VI  - 17
IP  - 5
DP  - 2023 Oct
TI  - Is the CRAFITY score a superior predictor of prognosis and adverse events in 
      hepatocellular carcinoma patients treated with locoregional-immunotherapy?
PG  - 1279-1288
LID - 10.1007/s12072-023-10535-8 [doi]
AB  - BACKGROUND: The level of C‑reactive protein (CRP) and alpha‑fetoprotein (AFP) in 
      immunotherapy (CRAFITY) score was associated with the prognosis of hepatocellular 
      carcinoma (HCC) patients treated with immunotherapy. Based on the CRAFITY score, 
      this study aimed to investigate the efficacy and safety of 
      locoregional-immunotherapy for treating HCC patients. METHODS: HCC patients who 
      received locoregional-immunotherapy were consecutively recruited at Sun Yat-sen 
      University Cancer Center in 2019. CRAFITY 0 score was defined as the AFP level 
      below 100 ng/ml and a CRP level of less than 1 mg/dl, CRAFITY 1 score was defined 
      as the AFP level of at least 100 ng/ml or the CRP level of at least 1 mg/dl, and 
      CRAFITY 2 score was defined as both the AFP level over 100 ng/ml and the CRP 
      level of more than 1 mg/dl. The primary outcomes were progression-free survival 
      (PFS) and overall survival (OS). The second outcomes were tumor response rate and 
      treatment-related adverse events (AEs). RESULTS: The median PFS for HCC patients 
      with the CRAFITY 0 score was not estimable. The PFS was 11.0 months [95% 
      confidence interval (CI) 7.2-14.9] and 6.0 months (95% CI 4.2-7.8) for patients 
      with CRAFITY 1 and 2 scores, respectively, with a significant difference between 
      the two groups (p < 0.001). HCC patients with CRAFITY 0, 1, and 2 scores had 
      3 years OS rates of 63.8%, 60.8%, and 32.1%, respectively, with statistical 
      differences among the three groups (p < 0.001). Patients with the CRAFITY 2 score 
      were more likely to experience fever than those with other scores (p < 0.05). A 
      greater CRAFITY score was correlated with a higher incidence of grade 3 and above 
      liver injury (p < 0.01). CONCLUSIONS: The CRAFITY score is a superior predictor 
      of prognosis and treatment-related AEs in HCC patients treated with 
      locoregional-immunotherapy.
CI  - (c) 2023. Asian Pacific Association for the Study of the Liver.
FAU - Guan, Renguo
AU  - Guan R
AUID- ORCID: 0000-0002-9487-7369
AD  - Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Mei, Jie
AU  - Mei J
AD  - Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Lin, Wenping
AU  - Lin W
AD  - Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Deng, Min
AU  - Deng M
AD  - Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Li, Shaohua
AU  - Li S
AD  - Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, China. lishaoh@sysucc.org.cn.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, China. 
      lishaoh@sysucc.org.cn.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 
      lishaoh@sysucc.org.cn.
FAU - Guo, Rongping
AU  - Guo R
AUID- ORCID: 0000-0003-2799-3463
AD  - Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, China. guorp@sysucc.org.cn.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, China. 
      guorp@sysucc.org.cn.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 
      guorp@sysucc.org.cn.
LA  - eng
GR  - No. 82172579/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230502
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
RN  - 0 (alpha-Fetoproteins)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular
MH  - alpha-Fetoproteins
MH  - *Liver Neoplasms/pathology
MH  - Prognosis
MH  - Immunotherapy/adverse effects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Adverse events
OT  - Alpha‑fetoprotein
OT  - C‑reactive protein
OT  - C‑reactive protein and alpha‑fetoprotein in immunotherapy score
OT  - Hepatic arterial infusion chemotherapy
OT  - Hepatocellular carcinoma
OT  - Overall survival
OT  - Programmed cell death 1
OT  - Progression-free survival
OT  - Transhepatic arterial chemotherapy and embolization
EDAT- 2023/05/02 12:44
MHDA- 2023/09/28 06:42
CRDT- 2023/05/02 11:08
PHST- 2023/01/30 00:00 [received]
PHST- 2023/04/08 00:00 [accepted]
PHST- 2023/09/28 06:42 [medline]
PHST- 2023/05/02 12:44 [pubmed]
PHST- 2023/05/02 11:08 [entrez]
AID - 10.1007/s12072-023-10535-8 [pii]
AID - 10.1007/s12072-023-10535-8 [doi]
PST - ppublish
SO  - Hepatol Int. 2023 Oct;17(5):1279-1288. doi: 10.1007/s12072-023-10535-8. Epub 2023 
      May 2.